Key Developments

On April 25, 2024, Regeneron Pharmaceuticals Inc., a pharmaceutical company, announced that it had collaborated with Mammoth Biosciences, Inc., a biotechnology company, to combine Mammoth Biosciences, Inc.’s platform with Regeneron’s effort to develop adeno-associated viral vectors (AAVs) that will use antibody-based targeting to enhance delivery of genetic medicine payloads to specific tissues and cell types. The collaboration helps to expand Regeneron’s genetic medicines presence with more gene editing programs.
On March 13, 2024, Ricoh Company, Ltd., a digital services company, announced a non-exclusive licensing agreement in the U.S. and Japan with ERS Genomics Limited, a biotechnology company, to provide broad access to the foundational CRISPR-Cas9 intellectual property, for access to the foundational CRISPR/Cas9 genome editing technology patents managed by ERS Genomics. CRISPR/Cas9 stands as a breakthrough gene editing technology, enabling modification of targeted genome sequences with ease. The technology is an essential tool in drug discovery research and finds application across various fields.
In August 2023, CrisprBits, a India-based biotech startup specializing in CRISPR gene editing, and Molbio Diagnostics, a India-based point of care diagnostic solutions, collaborated to introduce CRISPR in point of care (POC) tests
In January 2023, RegenOrthoSport, an orthopedic clinic in Mumbai, India, announced that it had received an approval from the National Ethics Committee Registry for Biomedical and Health Research (NECRBHR), under the Ministry of Health and Family Welfare for the use of Autologous Bone Marrow Aspirate Concentrate (BMAC) and Platelet Rich Plasma (PRP) on patients affected with musculoskeletal disorders
In December 2022, Merck KGaA, a global healthcare company, partnered with Synplogen, a startup from Kobe University, Kobe, Japan, through a non-binding MoU. Their goal is to combine expertise for development, manufacturing testing of gene therapies in Japan
In March 2021, Scribe Therapeutics Inc., a company specializing in molecular engineering and renowned for its cutting-edge CRISPR-based genetic medicine technologies, announced the successful closure of an oversubscribed Series B financing round, raising a remarkable US$ 100 million. This infusion of capital is earmarked for the continued advancement of Scribe Therapeutics Inc.'s tailored gene editing and delivery platforms, alongside the progression of a robust therapeutic pipeline targeting neurodegenerative disorders and other ailments characterized by significant unmet medical needs.